Sangamo Therapeutics (NASDAQ:SGMO) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $5.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com started coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They issued a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $2.67.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ:SGMO opened at $1.49 on Tuesday. The company has a 50 day moving average price of $0.88 and a two-hundred day moving average price of $0.68. The company has a market capitalization of $310.25 million, a PE ratio of -1.08 and a beta of 1.23. Sangamo Therapeutics has a 52 week low of $0.29 and a 52 week high of $1.77.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The firm had revenue of $0.36 million during the quarter, compared to analyst estimates of $11.40 million. Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. On average, sell-side analysts forecast that Sangamo Therapeutics will post -0.47 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGMO. Wasatch Advisors LP lifted its holdings in shares of Sangamo Therapeutics by 62.4% in the first quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after purchasing an additional 7,734,400 shares in the last quarter. Acadian Asset Management LLC raised its position in Sangamo Therapeutics by 4.0% in the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after buying an additional 192,385 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after acquiring an additional 1,528,600 shares in the last quarter. Marshall Wace LLP boosted its position in Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 207,476 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 1st quarter worth approximately $331,000. 56.93% of the stock is owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.